A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma

Kathy D. Miller, Patrick J. Loehrer, René Gonin, George Weber, Rafat Ansari, William Pletcher, John McClean, C. H. Spiridonidis, Joanne Mortimer

Research output: Contribution to journalArticle

7 Scopus citations


From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patients were treated for a total of 6 months or until disease progression. The median age was 66 (range 44-79) and the median KPS was 80. No patient had received prior chemotherapy. Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within 2 months of beginning therapy. The combination of methotrexate and AZT is an inactive regimen in pancreatic and hepatocellular carcinoma and is associated with considerable toxicity.

Original languageEnglish (US)
Pages (from-to)207-212
Number of pages6
JournalInvestigational New Drugs
Issue number2
StatePublished - Jan 1 1996



  • Hepatocellular carcinoma
  • Methotrexate
  • Pancreatic carcinoma
  • Thymidine synthesis
  • Zidovudine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this